2. Signaling Pathways
  3. Stem Cell/Wnt
  4. Oct3/4
  5. Oct3/4 Inhibitor

Oct3/4 Inhibitor

Oct3/4 Inhibitors (3):

Cat. No. Product Name Effect Purity
  • HY-116940
    Sm4
    		Inhibitor 99.01%
    Sm4 is a selective and orally active SOX18 inhibitor. Sm4 inhibits SOX18-DNA binding (IC50 = 97.5 μM); Sm4 disrupts the SOX18-RBPJ protein-protein interaction (IC50 = 42.3 μM). Sm4 blocks SOX18 DNA binding, disrupts multiple SOX18 protein-protein interactions with RBPJ, DDX1, DDX17, ILF3, SOX7 and STAT1, modulates SOX18 chromatin binding dynamics. Sm4 exerts anti‑angiogenic and anti‑lymphangiogenic effects, reduces tumor vascular density, triggers vascular defects in zebrafish, prolongs survival in mouse metastatic cancer models. Sm4 can be used for the research of breast cancer.
  • HY-133825
    Cyazofamid
    		Inhibitor 98.15%
    Cyazofamid exerts its bactericidal effect by impairing ATP production. Cyazofamid inhibits organic cation transporter 3 (OCT3) and OAT1, with IC50 values ​​of 1.54 and 17.3 μM, respectively.
  • HY-129108
    9-cis-UAB30
    		Inhibitor
    9-cis-UAB30 is a rexinoid agonist. 9-cis-UAB30 significantly decreases the proliferation, viability, and motility of both patient-derived xenografts (PDXs). 9-cis-UAB30 induced cell-cycle arrest as demonstrated by the significant increase in the percentage of cells in G1 and a decrease in the percentage of cells in S phase by downregulating SKP2 and/or 20S proteasome activity, which leads to increased p27kip1 protein stability. 9-cis-UAB30 downregulates the abundance of stem cell marker mRNAs (Oct4, Nanog, Sox2, nestin) and upregulates the abundance of differentiation marker mRNAs (β3-tubulin, NSE, HOXC9, GAP43). 9-cis-UAB30 has no adverse effects on the central nervous system and cardiovascular system at the tested dose. 9-cis-UAB30 can be used for the study of neuroblastoma, cutaneous T-cell lymphomas, and breast cancer.